Key Stages in the Development and Quality Control of the Lipoarabinomannan Detection Kit (Chemiluminescence Method)

Screening Strategies for Targets and Antibody Raw Materials

Lipoarabinomannan is a highly effective antigen, and its molecular structure comprises a mannan core, arabinan side chains, and terminal mannose caps. During development, it is necessary to select monoclonal antibody pairs targeting conserved epitopes of LAM, typically using antibody combinations against different glycosyl epitopes to reduce the specificity risks arising from cross-reactivity with different Mycobacterium species. In the raw material screening stage, antibody affinity can be determined by surface plasmon resonance (SPR) or biolayer interferometry, and a matrix of clinical negative samples should be used to assess nonspecific adsorption. After obtaining candidate antibodies, preliminary labeling process trials are required to evaluate the effects of chemiluminescent labels (such as acridinium ester derivatives) on antibody activity. A common practice is to react the label with the antibody at a certain molar ratio, and after purification, determine the labeling rate and immunoreactivity.

Construction and Optimization of the Chemiluminescence Immunoassay System

The core of a chemiluminescence kit includes a solid-phase carrier, labeled antibodies, a substrate system, and separation and washing steps. Currently, magnetic microparticles are commonly used as the solid phase due to their large surface area and rapid separation. During development, it is necessary to optimize the magnetic microparticle coating conditions (such as pH, ionic strength, and antibody concentration) to ensure uniform and stable coating. For signal amplification, an alkaline phosphatase-AMPPD system or a direct chemiluminescence mode can be selected; the latter requires no enzymatic catalysis and reacts rapidly. The entire reaction system needs to balance kinetic parameters to control the Hook effect while ensuring sensitivity. Generally, the risk of the Hook effect is reduced by adding a certain concentration of blocking agents or optimizing the sample dilution ratio. In addition, stability studies of the reagents (accelerated and real-time) are the basis for determining storage conditions and shelf life, and must be verified across multiple batches.

Key Points of Performance Verification and Quality Control

According to the guidelines for registration of in vitro diagnostic reagents, LAM detection kits must complete analytical performance evaluations such as limit of blank (LoB), limit of detection (LoD), limit of quantification (LoQ), linear range, precision, and accuracy. For example, precision evaluation must cover repeatability, intermediate precision, and reproducibility, using quality control materials containing different LAM concentrations for testing. Accuracy can be measured by recovery tests or comparison with reference methods, but it should be noted that there is currently no internationally recognized LAM reference material, so in-house assigned standard materials are often used. Clinical performance evaluation must include the target population (such as suspected active tuberculosis patients and healthy controls), calculate sensitivity, specificity, positive predictive value, and negative predictive value, and analyze consistency with the gold standard (culture or molecular testing). The data should clearly define the area under the receiver operating characteristic curve, but avoid absolute expressions such as "extremely high" or "perfect."

Registration Compliance and Post-Market Regulatory Considerations

In mainland China, LAM detection kits are Class III in vitro diagnostic reagents and require NMPA registration approval. The submission dossier should cover product risk analysis, technical requirements, production processes, stability studies, and clinical trial reports. Clinical trials must involve at least two tertiary Grade A hospitals, and the sample size should be calculated based on the preset sensitivity and specificity. The instructions for use must comply with the Guidelines for Drafting Instructions for In Vitro Diagnostic Reagents, clearly stating the intended use, detection principle, main components, storage conditions, clinical interpretation, and limitations. For example, it should be stated that "this kit is used for the auxiliary diagnosis of active tuberculosis and cannot be used alone as a basis for treatment decisions." After market launch, an adverse event monitoring and product quality review analysis system must be established to ensure batch-to-batch consistency. In addition, the industry calls for promoting the value assignment and traceability of LAM reference materials to improve the comparability and mutual recognition of results from different kits.